Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Otolaryngology



Depression and Survival in Patients With Head and Neck Cancer

[1] Andriani, [1] Rahayu

[1] Faculty of Medicine, Sebelas Maret University, Surakarta City, Central Java, Indonesia

Correspondence : dr.andriani9287362@gmail.com

Article History :
Received date : 2024/10/07
Revised date : 2024/11/25
Accepted date : 2024/12/19
Published date : 2024/01/10

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The interplay between depression and cancer, particularly in patients with head and neck cancer, has garnered increasing attention in recent years. **Literature Review:** The subsequent investigation in 2018 revealed that while treating major depression in cancer patients alleviated depressive symptoms, it did not significantly improve survival rates (Mulick et al., 2018). This finding raises crucial questions regarding the efficacy of current treatment modalities, highlighting the complexity of cancer care where psychological and biological factors interplay. A critical review in 2019 further elaborated on the relationship between cancer-related inflammation and depression, noting the high prevalence of depressive symptoms across various cancer types, including head and neck cancers (C. McFarland et al., 2021). The authors emphasized the need for addressing mental health issues to improve overall patient outcomes, particularly as the burden of depression escalates with disease progression. Finally, a population-based cohort study conducted in 2020 reaffirmed the association between depression and poorer survival outcomes in head and neck cancer patients, particularly those with advanced disease stages (Huang et al., 2022). The study highlighted the necessity for integrated psychological care within oncology settings, as undetected depression often remains untreated, adversely affecting both mood and survival rates. **Conclusion:** In conclusion, the reviewed literature collectively underscores the intricate relationship between depression and survival in patients with head and neck cancer. There is a pressing need for comprehensive mental health assessments and interventions as part of standard cancer care. The findings suggest that addressing depressive symptoms could potentially enhance both the quality of life and survival rates among these patients, warranting further research to explore effective treatment strategies.

Keyword: Depression, Survival, Head and Neck Cancer

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The interplay between depression and cancer, particularly in patients with head and neck cancer, has garnered increasing attention in recent years. The literature reveals a complex relationship where depression not only affects the quality of life but may also have implications for survival outcomes.

In 2010, (Mayr & M Schmid, 2010) highlighted the high prevalence of depression in cancer patients, particularly those with poor prognoses, such as pancreatic cancer. Their retrospective analysis suggested that while some studies indicated a negative impact of depression on survival, others, including a substantial review by Petticrew et al. (2002), noted that positive correlations were often derived from methodologically flawed studies. This inconsistency in findings underscores the necessity for further inquiry into the effects of psychological factors on cancer survival ((Mayr & M Schmid, 2010)).

Advancing to 2017, (Sherrill et al., 2017) emphasized the detrimental effects of depressive disorders on patients with head and neck cancer. They found a clear correlation between the presence of depression and poorer outcomes, including increased mortality. Their study reinforced the critical need for early screening and management of depressive symptoms, suggesting that untreated depression could lead to significant declines in both quality and quantity of life for these patients ((Sherrill et al., 2017)).

In 2018, (Mulick et al., 2018) investigated the impact of treating major depression in cancer patients, concluding that while treatment effectively alleviated depressive symptoms, it did not yield statistically significant improvements in survival rates. This raises important questions about the efficacy of current treatment modalities for depression in enhancing survival outcomes for cancer patients, suggesting that larger trials are necessary to ascertain any potential benefits ((Mulick et al., 2018)).

The following year, (C. McFarland et al., 2021) provided a critical review of cancer-related inflammation and depression, noting that depression is notably prevalent

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

across various cancer types, including head and neck cancers. They observed that the rates of depressive symptoms increase with advanced disease stages and treatment burdens, highlighting the psychosocial challenges faced by patients. The authors underscored the importance of addressing these mental health issues to improve overall patient outcomes ((C. McFarland et al., 2021)).

Finally, (Huang et al., 2022) conducted a population-based cohort study specifically focusing on head and neck cancer patients. Their findings reaffirmed the high prevalence of depression and its association with poorer survival outcomes, particularly in patients with advanced disease stages. They suggested that undetected depression often goes untreated, emphasizing the need for integrated psychological care within oncology settings to enhance both mood and survival rates ((Huang et al., 2022)).

Collectively, these studies illustrate the intricate relationship between depression and survival in patients with head and neck cancer, revealing a pressing need for comprehensive mental health assessments and interventions as part of standard cancer care.

LITERATURE REVIEW

The article "Pancreatic cancer and depression: myth and truth" by (Mayr & M Schmid, 2010) provides a comprehensive examination of the complex relationship between depression and cancer survival, specifically focusing on pancreatic cancer. The authors highlight the high prevalence rates of depression among cancer patients and its potential implications for overall survival. They suggest that depression may impair immune responses and contribute to higher rates of suicide, which could adversely affect patient outcomes.

A notable aspect of the article is its critical analysis of existing literature, particularly a retrospective analysis conducted by Sheibani-Rad et al. that indicated no significant impact of depression on survival in pancreatic cancer patients. This finding challenges the commonly held belief that depression universally correlates with poorer survival outcomes in cancer patients. Additionally, the authors reference various studies that have reported the benefits of group therapies in

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

extending survival rates, suggesting that psychosocial interventions may play a crucial role in managing depressive symptoms and potentially improving survival outcomes.

The article also emphasizes the ongoing debate within the research community regarding the relationship between depression and cancer mortality. (Mayr & M Schmid, 2010) note that while some reviews and meta-analyses have found consistent evidence linking depression with increased mortality, the reliability of these results varies based on study characteristics. For instance, the meta-analysis by Pinquart et al. is mentioned for its reassessment of the association between depression and cancer mortality, which persisted even after controlling for confounding medical variables.

The article "Effect of Treating Depressive Disorders on Mortality of Cancer Patients" by (Sherrill et al., 2017) offers a comprehensive examination of the interplay between depressive disorders and cancer outcomes, particularly focusing on mortality rates among patients with various types of cancer, including head and neck cancer. The authors underscore the significant impact that depressive disorders can have on both the quality and quantity of life, particularly in the context of cancer diagnosis and treatment.

The article presents a critical evaluation of existing literature that links the presence of depressive disorders with poorer clinical outcomes, emphasizing that these disorders can exacerbate morbidity and mortality in cancer patients. The authors note that the correlation between depression and adverse outcomes varies significantly based on factors such as cancer type, disease stage, and patient co-morbidities. This variability suggests that a one-size-fits-all approach to managing depression in cancer patients may be inadequate, and individualized treatment plans are essential for optimizing patient care.

One of the key insights from the article is the long-lasting nature of the effects of depressive disorders. The authors highlight the importance of early and continuous screening for depression throughout the cancer care continuum. This is particularly relevant for patients diagnosed with head and neck cancer, where the psychological

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

burden can be profound due to the visible and often debilitating nature of the disease and its treatment.

Moreover, the article critically discusses the implications of various treatment modalities for depressive disorders and their effects on mortality. Notably, the authors reference studies indicating that certain treatments, such as tricyclic antidepressants, may not only fail to improve mortality outcomes but could potentially increase them. This finding raises important questions about the safety and efficacy of antidepressant treatments in this vulnerable population, underscoring the need for further research to identify effective interventions.

The article "Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials" by (Mulick et al., 2018) addresses a critical intersection between mental health and oncology, particularly focusing on the relationship between comorbid depression and survival outcomes in cancer patients. The study is particularly relevant given the established understanding that comorbid depression is associated with poorer survival rates in individuals diagnosed with cancer.

The authors conducted a comparative analysis of survival outcomes between cancer patients with comorbid major depression who received targeted depression treatment and those who received only usual care. This approach is significant as it attempts to bridge a gap in existing literature, which the authors note lacks robust randomized clinical trials specifically examining the survival impacts of treating depression in cancer patients. The findings indicate that while depression treatment was effective in alleviating depressive symptoms, it did not yield statistically significant improvements in survival rates.

A critical evaluation of the material reveals several important considerations. Firstly, the study underscores a crucial limitation in the existing body of research; despite the high prevalence of depression among cancer patients, the absence of convincing evidence linking depression treatment to improved survival outcomes raises questions about the efficacy of current treatment paradigms. The authors suggest that the lack of substantial survival benefits could point to the complexity

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

of cancer as a disease, where multifactorial elements influence survival beyond the psychological state of the patient.

Moreover, the study calls for larger trials with extended follow-up periods to adequately assess potential modest but clinically significant effects of depression treatment on survival. This recommendation highlights an essential aspect of oncological research, emphasizing the need for a more nuanced understanding of how psychological interventions may interplay with biological and treatment-related factors in cancer care.

The article by (C. McFarland et al., 2021) provides a comprehensive examination of the interplay between cancer-related inflammation and depression, particularly in the context of head and neck cancer. The authors assert that depression is the most prevalent psychiatric disorder among cancer patients, with varying rates contingent upon cancer type, assessment methods, and patient demographics. This variability is particularly pronounced in head and neck cancer patients, who often face unique psychosocial challenges due to the physical manifestations of their illness, such as disfigurement and impairment of essential functions like taste and smell.

The authors highlight that approximately 25-30% of cancer patients experience depressive disorders during their treatment, with head and neck cancers demonstrating particularly high rates of depressive symptoms. This statistic is alarming, especially considering that the burden of depression often escalates with advanced disease stages and treatment-related symptoms. The authors effectively illustrate that the emotional and psychological toll of cancer is compounded by the physical morbidity associated with specific cancer types, notably in head and neck cancer, where the impact on quality of life can be profound.

A critical evaluation of the article reveals a well-structured argument supported by epidemiological data, which underscores the necessity of recognizing depression as a significant comorbidity in cancer care. The authors' discussion on the continuum of depressive symptoms—from normal responses to illness to major depressive episodes—provides valuable insights into the complexity of patient experiences.

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

This continuum is particularly relevant for healthcare providers who must navigate the psychological dimensions of cancer treatment.

Furthermore, (C. McFarland et al., 2021) emphasize the importance of addressing psychosocial issues that may arise concurrently with cancer treatment. These issues include family tensions, loss of autonomy, and adjustments to daily life, which can exacerbate depressive symptoms. The authors advocate for a more integrated approach to cancer care that includes mental health support, particularly for patients with head and neck cancer who may be disproportionately affected by psychological distress.

The article titled "The impact of depression on survival of head and neck cancer patients: A population-based cohort study" by (Huang et al., 2022) provides a comprehensive examination of the relationship between depression and survival outcomes in patients diagnosed with head and neck cancer. The authors highlight a critical gap in the understanding of how psychological factors, particularly depression, influence cancer treatment adherence and overall survival rates.

The study underscores that advanced stages of head and neck cancer often necessitate aggressive treatment protocols, including radiotherapy and chemotherapy, which can be challenging for patients already grappling with psychological distress. The prevalence of major depression among cancer patients, ranging from 13% to 50%, suggests that a significant number of individuals may not receive the necessary mental health support, leading to poorer treatment outcomes ((Huang et al., 2022)). This finding aligns with previous research indicating that pre-existing depression can lead to nonadherence to prescribed therapies, ultimately affecting survival rates ((Huang et al., 2022)).

A notable contribution of this article is its emphasis on the need for formal diagnosis and treatment of depression in cancer patients. The authors argue that many patients either overlook their mental health needs or lack access to appropriate psychological interventions, which can exacerbate their condition and hinder recovery. The call for integrating psychosocial oncology into multidisciplinary cancer care teams is particularly relevant, as it addresses the necessity of treating

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

mental health alongside physical health to improve patient outcomes ((Huang et al., 2022)).

Furthermore, the article discusses the heightened risk of suicidal ideation in patients experiencing post-cancer depression, linking it to body image concerns that often accompany head and neck cancer diagnoses. This aspect is critical as it highlights the multifaceted impact of cancer on a patient's mental health and the importance of addressing these issues proactively ((Huang et al., 2022)).

CONCLUSION

The interplay between depression and survival outcomes in patients with head and neck cancer is a significant area of research that has evolved over the years. The studies reviewed indicate that depression is prevalent among cancer patients, particularly those with head and neck malignancies, and is associated with poorer survival outcomes. The literature reveals a consistent trend where the presence of depressive disorders correlates with adverse clinical outcomes, emphasizing the need for early detection and management of mental health issues in this population.

In 2010, the examination of depression among cancer patients, particularly those with poor prognoses, highlighted that while some studies suggested a negative impact of depression on survival, others indicated methodological flaws in deriving these conclusions (Mayr & M Schmid, 2010). This inconsistency necessitates further research into psychological factors and their influence on cancer survival.

By 2017, the focus shifted specifically to head and neck cancer, where a clear correlation between depressive disorders and increased mortality was established (Sherrill et al., 2017). This study underscored the importance of screening for depression, as untreated symptoms could significantly impair both quality and quantity of life.

The subsequent investigation in 2018 revealed that while treating major depression in cancer patients alleviated depressive symptoms, it did not significantly improve survival rates (Mulick et al., 2018). This finding raises crucial questions regarding

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

the efficacy of current treatment modalities, highlighting the complexity of cancer care where psychological and biological factors interplay.

A critical review in 2019 further elaborated on the relationship between cancer-related inflammation and depression, noting the high prevalence of depressive symptoms across various cancer types, including head and neck cancers (C. McFarland et al., 2021). The authors emphasized the need for addressing mental health issues to improve overall patient outcomes, particularly as the burden of depression escalates with disease progression.

Finally, a population-based cohort study conducted in 2020 reaffirmed the association between depression and poorer survival outcomes in head and neck cancer patients, particularly those with advanced disease stages (Huang et al., 2022). The study highlighted the necessity for integrated psychological care within oncology settings, as undetected depression often remains untreated, adversely affecting both mood and survival rates.

In conclusion, the reviewed literature collectively underscores the intricate relationship between depression and survival in patients with head and neck cancer. There is a pressing need for comprehensive mental health assessments and interventions as part of standard cancer care. The findings suggest that addressing depressive symptoms could potentially enhance both the quality of life and survival rates among these patients, warranting further research to explore effective treatment strategies.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -
- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved

1. Mayr, M. & M Schmid, R., 2010. Pancreatic cancer and depression: myth and truth. ncbi.nlm.nih.gov
2. Sherrill, C., Smith, M., Mascoe, C., Bigus, E., & Abbitt, D., 2017. Effect of Treating Depressive Disorders on Mortality of Cancer Patients. ncbi.nlm.nih.gov
3. Mulick, A., Walker, J., Puntis, S., Burke, K., Symeonides, S., Gourley, C., Wanat, M., Frost, C., & Sharpe, M., 2018. Does depression treatment improve the survival of depressed patients with cancer? A long-term follow-up of participants in the SMaRT Oncology-2 and 3 trials.. [PDF]
4. C. McFarland, D., Riba, M., & Grassi, L., 2021. Clinical Implications of Cancer Related Inflammation and Depression: A Critical Review. ncbi.nlm.nih.gov
5. Huang, R. W., Chang, K. P., Marchi, F., Yuen Yung Loh, C., Lin, Y. J., Chang, C. J., & Kao, H. K., 2022. The impact of depression on survival of head and neck cancer patients: A population-based cohort study. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Otolaryngology
Copyright © International Medical Journal Corp. Ltd. All rights reserved